American regulators are working on a phased plan for the resumption of inspections of pharmaceutical factories, which was suspended due to the spread of coronavirus infection. The work is conducted jointly with the Centers for control and prevention (CDC), told the FDA.
In March, the FDA announced the suspension of inspection of manufacturing sites due to contamination risk employees COVID-19. The regulator said that the risk to inspectors are higher than for consumers in case of supply to the market drugs of poor quality. Instead of the usual inspections for quality control of drugs was carried out product testing at the border, and in case of revealing the poor quality of imported drugs was prohibited.
While continuing pandemic, U.S. regulators will continue to use alternative methods of quality control, inspections will not be performed until they are needed in the field of health.
However, together with CDC experts, the FDA started working on a plan for the resumption of control measures. For starters will be determined “when and where” in the future to begin inspections to ensure the safety of the inspectors.